gastric cancer
Conditions
Interventions
experimental group: autocrine PD-1 nano antibody MesO-CAR T combined with apatinib
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To enter the study group, you must meet all the following criteria: (1) Patients with recurrent or refractory advanced gastric malignancy (confirmed histologically or cytologically), (2) Patients who fail in second-line treatment or fail in first-line treatment and are unwilling to receive second-line treatment; (3) Age 18-80, male or female; (4) Expected survival time >= 3 months; (5) ECOG score 0-1; (6) Adequate venous access and no contraindications for peripheral blood mononuclear cell collection;
Exclusion criteria
Exclusion criteria: If you meet any of the following exclusion criteria, you shall not be enrolled into the group: (1) There is an active viral or bacterial infection that cannot be controlled by anti-infective treatment; (2) persons infected with hepatitis B or Hepatitis C virus who are serologically positive for HIV or syphilis and are not under control; (3) patients with immune-related diseases such as autoimmune diseases and organ transplants under treatment, or long-term use of immunosuppressive drugs such as glucocorticoids; (4) Patients with severe cardiopulmonary insufficiency, high blood pressure that cannot be controlled by drugs, unstable coronary artery disease (uncontrolled arrhythmia, unstable angina), uncompensable congestive heart failure, myocardial infarction within 6 months; (5) has any other serious medical condition that the investigator believes may affect the patient's treatment, follow-up, or evaluation.Including any uncontrolled neurological, psychiatric, immune-regulatory, metabolic and infectious diseases of clinical significance; (6) Prior to enrollment, received anticancer therapy (including clinical drug trials) at the following times: Subjects into groups before the chemotherapy drug withdrawal time is less than the chemotherapy treatment cycle; Research four weeks before the start of treatment or within less than the five half-life of drugs for anti-tumor therapy (including radiation therapy, chemotherapy, biological therapy or immunotherapy), with short time accurate (but the shortest time should not be less than 21 days); (7) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;disease control rate;progression-free survival;OS; | — |
Countries
China
Contacts
Public ContactQing Xu
Shanghai Tenth People's Hospital
Outcome results
None listed